Verastem appoints Jonathan Pachter head of research
This article was originally published in Scrip
Executive Summary
Verastem, a biopharmaceutical company developing cancer drugs, has appointed Dr Jonathan Pachter vice-president and head of research. Dr Pachter previously served as head of cancer biology at OSI Pharmaceuticals, where his team was responsible for the development of EMT (epithelial-mesenchymal transition) models to discover drugs that inhibit this process and the cancer stem cells that result.